Overview
ACOG market data
Price History
ACOG price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 8.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -232.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.50 – $10.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $192.7M · P/B 2.26 · P/S 17.80.
Company News
Alpha Cognition shares are trading higher after the company reported better-than-expected Q2 sales results.Benzinga · Aug 14, 2026, 1:24 PM
Alpha Cognition Q2 2026 Earnings Call TranscriptBenzinga · Aug 13, 2026, 9:20 PM
Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M EstimateBenzinga · Aug 13, 2026, 8:09 PM
Alpha Cognition Announces European Patent Grant For Crystalline Benzgalantamine, ZUNVEYL's Active Ingredient, With Potential Protection Into 2042Benzinga · Jul 29, 2026, 12:33 PM
This Travelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Jul 10, 2026, 11:50 AM
Raymond James Initiates Coverage On Alpha Cognition with Outperform Rating, Announces Price Target of $20Benzinga · Jul 10, 2026, 11:00 AM
8-K filing — Alpha Cognition Inc. (ACOG)SEC EDGAR · Jun 23, 2026, 2:35 PM
Alpha Cognition Appoints Robert Wills As Board Chairman, Succeeding Len MertzBenzinga · Jun 23, 2026, 12:40 PM
Alpha Cognition Enrolls First Patient In RESOLVE, Phase 4 Post-Marketing Clinical Study To Further Evaluate Tolerability Profile, Treatment Experience Associated With ZUNVEYL In Routine Clinical PracticeBenzinga · Jun 16, 2026, 12:45 PM
Alpha Cognition Reports Top-Line Results From BEACON Real-World Study Of ZUNVEYLBenzinga · Jun 9, 2026, 12:10 PM